Associated tags: Prime editing, Gene editing, Patient, Pharmaceutical industry, Vaccine, News
Locations: SAN FRANCISCO, BOSTON, SWITZERLAND, SPAIN, EUROPE, BELGIUM, UK, LONDON, CA, CAMBRIDGE, MA, US, BALTIMORE
FDA,
Process,
Chronic granulomatous disease,
Mutation,
Mouse,
Cell,
CGD,
Food,
Hematology,
Life,
U.S. FDA,
IND,
Neutrophil,
NADPH,
Patient,
Society,
Immunology,
Stem cell,
Fungus,
Health,
NCF1,
Pharmaceutical industry CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be presented today at an oral presentation during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore. Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.
Key Points:
- The data will be presented today at an oral presentation during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore.
- Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.
- Prime Medicine is advancing an ex vivo Prime Editing program, PM359, that aims to correct the predominant mutation in NCF1 in CGD patient CD34+ hematopoietic stem cells (HSCs) and restore NADPH oxidase function.
- In today’s presentation at ASGCT, Prime Medicine highlighted data from a series of in vivo non-clinical studies using human CGD patient CD34+ HSCs.
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting (Baltimore, May 7-11, 2024); and TIDES USA Oligonucleotide & Peptide Therapeutics Conference (Boston, May 14-17, 2024).
Key Points:
- “In the short time since Prime Editing was first discovered, we have made incredible strides advancing this technology, developing and optimizing Prime Editors for programs across our core areas of focus, and creating new delivery systems that we believe will permit our Prime Editors to safely and effectively access target tissue,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
- In addition to our presentations, we congratulate our Co-Founder, David Liu, on receiving the ASGCT Outstanding Achievement Award, highlighting his work in the gene editing field, including his contributions to the discovery and advancement of Prime Editing.
- We look forward to coming together with the scientific research community and highlighting our leading position in the field of next-generation gene editing.”
Details of the presentations are as follows.
- Presentation Name: Advancing LNP Screening to Incorporate Automated, High-Throughput Readouts
Sequence,
Composition,
Liver,
RHO,
Immunotherapy,
Investment,
FDA,
Research and development,
HSC,
Food,
CGD,
Patent,
SCIP,
Lung,
Ataxia,
Cystic Fibrosis Foundation,
Hematology,
Administration,
Patient,
Target,
IND,
AAV,
CTA,
Pharmaceutical industry CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.
Key Points:
- “In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients.
- This funding will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
- Gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
- In January 2024, Prime Medicine announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer.
Retrieved on:
Wednesday, February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
Key Points:
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
TD Cowen 44th Annual Healthcare Conference: Keith Gottesdiener, M.D., President and Chief Executive Officer, will participate in a panel discussion, “Emerging Genetic Therapy Approaches,” on Wednesday, March 6, 2024, at 12:50 p.m.
- ET in Boston, MA.
- Jefferies Biotech on the Bay Summit: Company management will host 1x1 investor meetings on Tuesday, March 12, 2024, in Miami Beach, FL.
- A replay of the webcast will be available on the Prime Medicine website for 30 days following the event.
Retrieved on:
Tuesday, February 20, 2024
Attention,
Lexington Avenue,
Jefferies Group,
J.P. Morgan & Co.,
Prospectus,
BMO Capital Markets,
Sale,
Exercise,
Telephone,
Form,
Broadridge Financial Solutions,
Madison Avenue,
S-3,
Jefferies,
Security (finance) All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine.
Key Points:
- All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine.
- The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
- J.P. Morgan, Jefferies, TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering.
- The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.
Retrieved on:
Thursday, February 15, 2024
Attention,
Lexington Avenue,
Jefferies Group,
J.P. Morgan & Co.,
BMO Capital Markets,
Telephone,
Sale,
Exercise,
Broadridge Financial Solutions,
Madison Avenue,
Jefferies,
Security (finance) Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock.
Key Points:
- Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock.
- The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $140.0 million, excluding any exercise of the underwriters' option to purchase additional shares.
- All of the shares and pre-funded warrants in the offering are to be sold by Prime Medicine.
- J.P. Morgan, Jefferies, TD Cowen and BMO Capital Markets are acting as joint book-running managers for the offering.
Retrieved on:
Wednesday, February 14, 2024
Attention,
Lexington Avenue,
Jefferies Group,
J.P. Morgan & Co.,
BMO Capital Markets,
Telephone,
Sale,
Broadridge Financial Solutions,
Madison Avenue,
Jefferies,
Security (finance) Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
Key Points:
- Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
- All of the shares of common stock in the proposed offering are to be sold by Prime Medicine.
- The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- J.P. Morgan, Jefferies, TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
Retrieved on:
Thursday, February 1, 2024
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:00 p.m.
Key Points:
- CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:00 p.m.
- ET in New York, NY.
- A live audio webcast of the fireside chat will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com.
- A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.
Retrieved on:
Thursday, January 25, 2024
Cystic fibrosis,
Patient,
Pancreas,
Research,
Cystic Fibrosis Foundation,
Urinary tract infection,
CFTR,
DSM-IV codes,
Nonsense,
Mutation,
Disease,
Mucus,
Vaccine Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
Key Points:
- Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
- Through hotspot editing, the Company aims to address multiple mutations at mutational hotspots with a small number of Prime Editors.
- Prime Medicine has begun preclinical research to use hotspot Prime Editors to correct the G542X nonsense CFTR mutation, and plans to extend this work to develop hotspot Prime Editors for other clusters of CFTR mutations.
- Prime Medicine is eligible for an additional $6 million upon achieving certain preclinical milestones, with up to $3 million in supplementary funding upon mutual agreement.
Liver,
Bachelor of Science,
Biotechnology,
Anticalin,
Foghorn,
Research,
University,
S.A.C. Capital Advisors,
Therapy,
CIBC World Markets,
Patient,
Management CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
Key Points:
- CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
- A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.
- “I am delighted to welcome Allan to Prime Medicine.
- He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
